Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 7, 2006; 12(5): 784-790
Published online Feb 7, 2006. doi: 10.3748/wjg.v12.i5.784
Published online Feb 7, 2006. doi: 10.3748/wjg.v12.i5.784
Table 1 Baseline characteristics
| Complete Ribavirin treatment(n = 141) | Discontinued Ribavirin treatment(n = 32) | All patients | |||
| Group A | Group B | Group C | Group D | ||
| Characteristic | (n = 93) | (n = 48) | (n = 11) | (n = 21) | (n = 173) |
| Median age (yr) | 5112 | 561 | 592 | 50 | 53 |
| (range) | (20 - 73) | (25 - 70) | (53 - 73) | (29 - 73) | (20 - 73) |
| Male (%) | 66 (71.0)3 | 16 (33.3)3 | 5(50.0) | 13 (61.9) | 100 (57.8) |
| Body weight | |||||
| 60 kg or more (%) | 60 (64.5) | 23 (47.9) | 6 (54.5) | 12 (57.1) | 101 (58.3) |
| Ribavirin dose by weight | |||||
| 12 mg/kg or more (%) | 24 (25.8) | 20 (41.7) | 4 (36.4) | 9 (42.8) | 57 (32.9) |
| Creatinine clearance (mL/min) | 11045 | 924 | 855 | 101 | 102 |
| (range) | (53 - 261) | (46 - 167) | (60 - 111) | (41 - 203) | (41 - 261) |
| HCV RNA level | |||||
| 500 kIU/mL or more (%) | 44 (47.3) | 22 (45.8) | 4 (36.4) | 9 (42.8) | 79 (45.7) |
| Genotype 2a (%) | 67 (72.0) | 28 (58.3) | 6 (54.5) | 13 (61.9) | 114 (65.9) |
- Citation: Furusyo N, Katoh M, Tanabe Y, Kajiwara E, Maruyama T, Shimono J, Sakai H, Nakamuta M, Nomura H, Masumoto A, Shimoda S, Takahashi K, Azuma K, Hayashi J, Group KULDS. Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Disease Study Group. World J Gastroenterol 2006; 12(5): 784-790
- URL: https://www.wjgnet.com/1007-9327/full/v12/i5/784.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i5.784